AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03096275 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CYC
Description: Patients were treated with Glucocorticoids and cyclophosphamide sequentially with azathioprine
Study NCT03096275 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucocorticoids
Description: Patients in the experimental group and comparator group were treated with Glucocorticoids and then gradually tapered
Study NCT03794973 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TOL-3021
Description: TOL-3021 1 mg is a bacterial plasmid expression vector containing the coding sequences for the human proinsulin (hINS) gene.
Study NCT03794973 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: TOL-3021 Placebo
Description: TOL-3021 Placebo
Study NCT00823173 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ESBA105
Description: ESBA105 eye drops (10mg/mL), initially applied in hourly dosing intervals, followed by later dose tapering (prolongation of dosing intervals)
Study NCT01749488 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Designated dietitian for the ward
Description: This is a randomized cluster trial. The centers randomized into this arm will designate a dietitian who will help the ward implement current recommendations for the nutrition of patients undergoing intensive care.
Study NCT02803203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: osimertinib
Study NCT02803203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Study NCT02024854 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: skin-to-skin
Study NCT02024854 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standard care
Study NCT01814956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipoplus 20%
Description: Lipoplus 20% (MCT/LCT/FO) i.v. lipid emulsion for parenteral nutrition
Study NCT03694587 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aktren® 200 mg überzogene Tabletten (Ibuprofen)
Description: one dose of Aktren® 200 mg überzogene Tabletten (Ibuprofen tablet)
Study NCT04076475 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: neuromuscular electrical stimulation
Description: Participants will receive muscular electrical stimulation on quadriceps muscle and abdominal muscles for 30 min/day for 10 days
Study NCT03110198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesalazine with hydrocortisone sodium succinate
Description: Mesalazine with hydrocortisone sodium succinate rectal administration at bedtime 4g，100mg/100 ml, once daily for induction of remission
Study NCT03833375 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision Aid
Description: Shared-decision making tool
Study NCT01480479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rindopepimut (CDX-110) with GM-CSF
Description: Two intradermal injections two weeks apart, followed by monthly injections until tumor progression or intolerance.~Each dose will be 0.8 mL containing approximately 500 mcg CDX-110 and 150 mcg GM CSF.
Study NCT01480479 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: 150 to 200 mg/m2 for 5 days during each 28-day cycle for a minimum of six cycles or a maximum of 12 cycles, or until intolerance or progression.
Study NCT01480479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 150 to 200 mg/m2 for 5 days during each 28-day cycle for a minimum of six cycles or a maximum of 12 cycles, or until intolerance or progression.
Study NCT01480479 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: KLH
Description: Two intradermal injections two weeks apart, followed by monthly injections until tumor progression or intolerance. Each dose will be 0.8mL containing approximately 100mcg of KLH.
Study NCT04370964 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Lausanne Trilogy Play
Description: Trilogical game of Lausanne (Lausanne Trilogue Play in English abbreviated LTP), which allows an evaluation of the family alliance. This systematic observation provides a snapshot of the family structure and its adaptive abilities. It is based on the assumption that the ability to solve small tasks is representative of the ability to solve more important tasks.The LTP consists of modelling the different possibilities of interaction in a triad according to a four-part scenario: 1) one parent plays with the child, the other parent is simply present; 2) the parents switch roles; 3) both parents play together with the child; and 4) both parents have to talk together.
Study NCT04370964 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Lausanne Family Play
Description: Lausanne Family Play (LFP) is a game situation adapted to families with more than one child. Thus, like the LTP, the LFP takes place in four phases:1) one parent plays with siblings while the other is in a third-observer position; 2) the parents reverse their roles;3) children play while parents are talking and 4) family members play together.
Study NCT00371111 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal injection of Triamcinolone
Description: 4 mg of Triamcinolone
Study NCT00371111 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal injection of Avastin
Description: Injection of 1.25 mg of Avastin and
Study NCT03430583 — intervention group
Intervention type: DRUG
Intervention: MZ101
Description: Drug
Study NCT00866892 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Irrigation
Description: irrigation
Study NCT00866892 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No irrigation
Description: no irrigation
Study NCT00556192 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rituximab
Description: 1. Rituximab of 1000 mg given 2 weeks apart. On day the of rituximab, and 'pulse' methylprednisolone 250mg IV be given followed by prednisolone 30mg/day from Day 2 to Day 5.~2. A treatment dose rituximab of 1000mg given 2 weeks apart and 'pulse' methylprednisolone 250mg IV be given followed by prednisolone 30mg/day from Day 2 to Day 5, and 'pulse' cyclophosphamide 500mg/m2 at baseline and day 14.~3. Sequential therapy with oral cyclophosphamide (50 to 100 mg/day) for 6 months followed by azathioprine (up to 2.5mg/kg/day) for maintenance up to 12 months. Oral prednisolone will be given at 0.5 mg/kg/day (up to 30 mg daily) for 4 weeks, tapered by 5 mg every 2 weeks thereafter until 5mg /day for the rest of the study period.
Study NCT03789890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1902607
Description: BAY1902607 is administered once orally as tablets on Day 2 of study period 1 and on Day 4 of study period 2.
Study NCT03789890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole is administered at a dose of 200 mg once a day (oral solution of 10 mg mL-1) on Day 1 to Day 14 of study period 2.
Study NCT04720495 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: One stage ridge splitting with simultaneous implant placement
Description: A full mucoperiosteal flap was raised using the sharp periosteal elevator to expose the bone crestally and buccally.~An inverted U-shaped bone cut, down to the cancellous bone, was done in the undercut area with a piezoelectric device.~The horizontal bone cut was made apical to the most concave point in the undercut area with a distance of 3 mm.~The two vertical bone cuts were placed at least 1 mm away from the adjacent roots and extended beyond the undercut area.~The released bone end was minimally elevated using a periosteotome through a greenstick fracture.~All implants were installed with the implant shoulders flush to the bone level using a low-speed drilling procedure.
Study NCT04720495 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Two-stage ridge splitting with implant placement
Description: The first surgery is the same as one stage ridge splitting Four weeks later, after revascularization between the bone block and the mucoperiosteum, the second surgery will be performed.~A crestal incision was done and the envelope flap slightly elevated to preserve the blood supply.~The implants will be placed in the same manner as one stage ridge splitting
Study NCT02962219 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pre-operative Exercise Programme (my-PEP)
Description: A pre-operative personalised exercise programme (my-PEP) consisting of: 1) actions to promote exercise, using behavioural change techniques (BCTs), 2) home inspiratory muscle training (IMT), 3) a home exercise programme (HEP) - which is also current standard care, 4) a 4 week hospital-supervised aerobic and muscle strengthening programme (Hos-PEP) .
Study NCT02962219 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Home Exercise Programme (HEP)
Description: Written advice on exercise at home
Study NCT02440295 — intervention group
Intervention type: PROCEDURE
Intervention: Lower Extremity Amputation
Study NCT02440295 — intervention group
Intervention type: DEVICE
Intervention: SPY Elite Imaging System
Description: The SPY Elite Imaging System is an adjunctive tool that can be used to assess tissue perfusion in real-time and provides surgeons with information that may change their operative plan before leaving the operating room. (http://novadaq.com/products/spy-elite) The system is comprised of two components, the first is the Spy Elite Kit, which is a single-use package containing one 25 mg vial of indocyanine green, one 10 ml vial of sterile Water for injection, and one SPY Elite sterile drape. The second component to the system is the SPY Elite Device which contains a near-infrared light source that illuminates the fluorescent agent within the tissues, an HD video camera captures the intensity of fluorescent marker in real-time, and software that allows the user to capture relative and absolute perfusion values within the surgical field.
Study NCT02440295 — intervention group
Intervention type: DRUG
Intervention: Indocyaine Green
Description: Indocyaine Green (ICG) is a non-nephrotoxic fluorescent imaging agent with a half-life of 2.5-3 minutes that is administered intravenously.
Study NCT03043729 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Oxaliplatin 85 mg/m\^2, as 2h infusion on Day 1 (Arm A + Arm B)
Study NCT03043729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 85 mg/m\^2, as 2h infusion on Day 1 (Arm A + Arm B)
Study NCT03043729 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU
Description: 5-FU 400 mg/m\^2 i.v. as bolus on Day 1 and 2400 mg/m\^2 as 46 h infusion q2w (Arm A + Arm B)
Study NCT03043729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 5-FU 400 mg/m\^2 i.v. as bolus on Day 1 and 2400 mg/m\^2 as 46 h infusion q2w (Arm A + Arm B)
Study NCT03043729 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: Leucovorin 350 mg/m\^2 i.v. as 2h infusion on Day 1 (Arm A + Arm B)
Study NCT03043729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Leucovorin 350 mg/m\^2 i.v. as 2h infusion on Day 1 (Arm A + Arm B)
Study NCT03043729 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aflibercept
Description: Aflibercept 4 mg/kg BW i.v. on Day 1 q2w (Arm B, Cycles 1 to 5)
Study NCT02469532 — intervention group
Intervention type: DEVICE
Intervention: Balloon Angioplasty
Description: Device: Balloon Angioplasty Selection is driven by preference of the operator
Study NCT02469532 — intervention group
Intervention type: DEVICE
Intervention: Atherectomy System
Description: Device: Orbital or Directional or Laser Atherectomy Systems Atherectomy selection is driven by preference of the operator
Study NCT00862654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clobetasol propionate shampoo (4/week) - ketoconazole shampoo (2/week)
Description: Association: clobetasol propionate shampoo \& ketoconazole shampoo
Study NCT00862654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clobetasol propionate shampoo (2/week) - ketoconazole shampoo (2/week)
Description: Association: clobetasol propionate shampoo \& ketoconazole shampoo
Study NCT00862654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clobetasol propionate shampoo (2/week)
Description: Monotherapy with clobetasol propionate shampoo
Study NCT00862654 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketoconazole shampoo (2/week)
Description: Monotherpay ketoconazole shampoo (2/week)
Study NCT04179435 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Behavioral testing on cognitive computerized tasks
Description: Testing on cognitive computerized tasks
Study NCT04179435 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: brain MRI
Description: Brain MRI scans
Study NCT04179435 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: TMS
Description: Measure of the cortical inhibitory capacity using TMS measures
Study NCT02712177 — intervention group
Intervention type: BIOLOGICAL
Intervention: 4CMenb
Study NCT02712177 — intervention group
Intervention type: BIOLOGICAL
Intervention: diphtheria,tetanus,pertussis+polio+Hepatitis B+HiB
Study NCT02432950 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02186743 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Personalized Dietary Advice
Description: Personalized dietary advice based on a commercially available blood test. Participants will be instructed to avoid eating selected foods for the duration of the intervention period (4 weeks). Some foods will be acceptable to consume every four days in rotation diet fashion.
Study NCT02186743 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized Dietary Advice
Description: Personalized dietary advice based on a commercially available blood test. Participants will be instructed to avoid eating selected foods for the duration of the intervention period (4 weeks). Some foods will be acceptable to consume every four days in rotation diet fashion.
Study NCT00253890 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trazodone
Description: 50 mg 1-3 capsules at bedtime for 3 months
Study NCT00253890 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1-3 at bedtime
Study NCT03917303 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: episodic treatment with subcutaneous adalimumab for 6 months
Study NCT03917303 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard step-up care
Description: conventional step-up care starting with corticosteroids
Study NCT02015520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clazakizumab
Study NCT02015520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Matching with Clazakizumab)
Study NCT02075736 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: KTP laser
Study NCT03096275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucocorticoids
Description: Patients in the experimental group and comparator group were treated with Glucocorticoids and then gradually tapered
Study NCT03096275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTX
Description: Patients in the experimental group are treated with Glucocorticoids combined with MTX and MMF
Study NCT03096275 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZA
Description: Patients in the active comparator group were treated with Glucocorticoids combined with CYC followed by AZA
Study NCT03212521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glecaprevir/Pibrentasvir
Description: Glecaprevir/pibrentasvir 100 mg/40 mg co-formulated tablets taken orally as 3 tablets once a day.
Study NCT01356784 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tailored Physical Activity
Description: Health counselling (1,5h) and graded physical activity (3×50 min/week in 10 weeks)
Study NCT01356784 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Chronic Pain Self-management Programme
Description: Health counselling (1,5h) and 'Chronic Pain Self-management Program' (2,5h in 6 weeks)
Study NCT01356784 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Health counselling
Description: Health guidance (1,5h)
Study NCT02923882 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: '$100Kitchen and improved cookstove'
Study NCT00621049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel/Carboplatin/Bevacizumab/Erlotinib
Description: Docetaxel 75mg/m2 IV D1 Carboplatin AUC=6 IV D1 Bevacizumab 15mg/kg IV D1~Docetaxel should be administered before carboplatin.~After completion of four cycles of treatment, patients in Cohort A will then proceed with Maintenance treatment defined as follows:~Maintenance Treatment for patients in Cohort A:~Bevacizumab 15mg/kg IV D1 Erlotinib 150mg PO daily~Treatment cycle = 21 days. Patients will complete 8 cycles (24 weeks) of maintenance therapy unless there is evidence of disease recurrence or unacceptable toxicity.
Study NCT00621049 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel/Carboplatin
Description: Adjuvant Treatment Cohort B:~Docetaxel 75mg/m2 IV D1 Carboplatin AUC=6 IV D1~Docetaxel should be administered before carboplatin.~Treatment cycle = 21 days. Patients in Cohort B will complete 4 cycles of treatment.
Study NCT01587937 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antibiotic stewardship audit-and-feedback to prescribers of patients receiving 3rd or 10th day of targeted broadspectrum antibiotics
Description: See primary outcome for list of targeted drugs. See citations for previous publications describing the intervention.
Study NCT02707861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibalizumab
Description: Intravenous infusion of humanized monoclonal antibody binding with a region of Domain 2 of CD4 receptor, blocking post-attachment conformational changes necessary for HIV cell entry
Study NCT02712177 — intervention group
Intervention type: BIOLOGICAL
Intervention: conjugated pneumococcal vaccine
Study NCT01814956 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lipofundin N 20%
Description: Lipofundin N 20% (LCT, soy bean oil) i.v. lipid emulsion for parenteral nutrition
Study NCT02478489 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral naltrexone (PO-NTX)
Description: oral naltrexone
Study NCT02075736 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TUR-P
Description: device
Study NCT02813369 — intervention group
Intervention type: DRUG
Intervention: naloxegol
Description: non-interventional study where patients are exposed to naloxegol during normal clinical practice
Study NCT02813369 — intervention group
Intervention type: DRUG
Intervention: non-PAMORA laxative
Description: non-interventional study where patients are exposed to non-peripherally acting mu-opioid receptor antagonist (PAMORA) laxative
Study NCT00639795 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic Paravertebral Nerve Block
Description: One Single-injection, thoracic peripheral nerve blockade performed intraoperatively following patient induction with general endotracheal anesthesia
Study NCT00639795 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Thoracic Paravertebral Nerve Block
Description: Sham single-injection thoracic peripheral nerve blockade following patient induction with general endotracheal anesthesia
Study NCT02355275 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Home Exercise Program
Description: All patients will be provided with a Thera-Band® Loop and Band and handout describing home exercises to be performed 3 times a week for 4 weeks.
Study NCT02531737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vargatef®
Description: Patients will be treated to oral nintedanib (vargatef®) 400 mg/d on days 2 to 21 of a 3-week cycle
Study NCT02531737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Patients will be treated to IV docetaxel 75 mg/m² on day 1 of evry 3-week cycle
Study NCT00710775 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: surgical replacement of the aortic stenotic valve
Description: Prior to surgical removal of the aortic valve, the native valve will be dilated under direct vision of the surgeon using a standard valve dilation balloon. The HLT valve will be loaded into a short version of the delivery catheter system and the catheter will be passed across the native valve.Measurements will be taken of the device relative to the anatomic structures of the heart. Once complete, the implant is removed from the native valve and the surgical valve replacement procedure is completed.
Study NCT02707861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optimized Background Regimen
Description: An investigator-selected, standard-of-care combination regimen of antiretroviral agents for treating HIV-1 infection, selected based upon patient treatment history and the results of previous viral resistance testing. The combination must contain at least one agent other than ibalizumab to which the patient's virus is sensitive (susceptible).
Study NCT00560430 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: telmisartan
Description: 80 mg per day, orally, weeks 1-14
Study NCT00560430 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: telmisartan
Description: 80 mg per day; orally, weeks 1 and 2; 160 mg per day; orally, weeks 3-14
Study NCT00560430 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo; orally weeks 1-14